Literature DB >> 25251599

Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.

Patrick Reichl1, Mirko Dengler, Franziska van Zijl, Heidemarie Huber, Gerhard Führlinger, Christian Reichel, Wolfgang Sieghart, Markus Peck-Radosavljevic, Markus Grubinger, Wolfgang Mikulits.   

Abstract

UNLABELLED: In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes. Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-β signaling. Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells. Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo. Importantly, Axl knockdown severely impaired resistance to TGF-β-mediated growth inhibition. Analysis of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-β. Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-β target genes such as PAI1, MMP9, and Snail as well as augmented TGF-β1 secretion in mesenchymal HCC cells. Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival. In addition, elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients.
CONCLUSION: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-β-mediated HCC progression and a promising target for HCC therapy.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25251599      PMCID: PMC4450343          DOI: 10.1002/hep.27492

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

Review 1.  Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.

Authors:  Gianluigi Giannelli; Erica Villa; Michael Lahn
Journal:  Cancer Res       Date:  2014-03-17       Impact factor: 12.701

Review 2.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 3.  Axl-dependent signalling: a clinical update.

Authors:  Vyacheslav A Korshunov
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

4.  A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression.

Authors:  Franziska van Zijl; Sabine Mall; Georg Machat; Christine Pirker; Robert Zeillinger; Andreas Weinhaeusel; Martin Bilban; Walter Berger; Wolfgang Mikulits
Journal:  Mol Cancer Ther       Date:  2011-03-01       Impact factor: 6.261

5.  Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes.

Authors:  Miguel M Murillo; Gaelle del Castillo; Aránzazu Sánchez; Margarita Fernández; Isabel Fabregat
Journal:  Oncogene       Date:  2005-06-30       Impact factor: 9.867

Review 6.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

8.  TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions.

Authors:  Shigeo Mori; Koichi Matsuzaki; Katsunori Yoshida; Fukiko Furukawa; Yoshiya Tahashi; Hideo Yamagata; Go Sekimoto; Toshihito Seki; Hirofumi Matsui; Mikio Nishizawa; Jun-ichi Fujisawa; Kazuichi Okazaki
Journal:  Oncogene       Date:  2004-09-23       Impact factor: 9.867

9.  Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma.

Authors:  A P Tsou; K M Wu; T Y Tsen; C W Chi; J H Chiu; W Y Lui; C P Hu; C Chang; C K Chou; S F Tsai
Journal:  Genomics       Date:  1998-06-15       Impact factor: 5.736

10.  AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.

Authors:  M Z Xu; S W Chan; A M Liu; K F Wong; S T Fan; J Chen; R T Poon; L Zender; S W Lowe; W Hong; J M Luk
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

View more
  61 in total

Review 1.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Authors:  Kavitha Balaji; Smruthi Vijayaraghavan; Lauren Averett Byers; Khandan Keyomarsi; Lixia Diao; Pan Tong; Youhong Fan; Jason Pw Carey; Tuyen N Bui; Steve Warner; John V Heymach; Kelly K Hunt; Jing Wang
Journal:  Mol Cancer Res       Date:  2016-09-26       Impact factor: 5.852

3.  Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

Authors:  Guoan Zhang; Meng Wang; Hongli Zhao; Wen Cui
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

4.  Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells.

Authors:  Irene Scharf; Lisa Bierbaumer; Heidemarie Huber; Philipp Wittmann; Christine Haider; Christine Pirker; Walter Berger; Wolfgang Mikulits
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

5.  Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro.

Authors:  Hua-Yu Zhu; Wen-Dong Bai; Jun Li; Ke Tao; Hong-Tao Wang; Xue-Kang Yang; Jia-Qi Liu; Yun-Chuan Wang; Ting He; Song-Tao Xie; Da-Hai Hu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

6.  Overexpression of YWHAZ as an independent prognostic factor in adenocarcinoma of the esophago-gastric junction.

Authors:  Nobuyuki Watanabe; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Takuma Ohashi; Wataru Okajima; Toshiyuki Kosuga; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Hitoshi Tsuda; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

7.  WNK1 collaborates with TGF-β in endothelial cell junction turnover and angiogenesis.

Authors:  Ankita B Jaykumar; Sakina Plumber; David M Barry; Derk Binns; Chonlarat Wichaidit; Magdalena Grzemska; Svetlana Earnest; Elizabeth J Goldsmith; Ondine Cleaver; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-22       Impact factor: 12.779

8.  A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Thomas C C Yau; Riccardo Lencioni; Wattana Sukeepaisarnjaroen; Yee Chao; Chia-Jui Yen; Wirote Lausoontornsiri; Pei-Jer Chen; Theeranun Sanpajit; Aaron Camp; Donna S Cox; Robert C Gagnon; Yuan Liu; Kristen E Raffensperger; Diptee A Kulkarni; Howard Kallender; Lone Harild Ottesen; Ronnie T P Poon; Donald P Bottaro
Journal:  Clin Cancer Res       Date:  2016-11-07       Impact factor: 12.531

9.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Authors:  Julia Boshuizen; Louise A Koopman; Oscar Krijgsman; Aida Shahrabi; Elke Gresnigt- van den Heuvel; Maarten A Ligtenberg; David W Vredevoogd; Kristel Kemper; Thomas Kuilman; Ji-Ying Song; Nora Pencheva; Jens Thing Mortensen; Marnix Geukes Foppen; Elisa A Rozeman; Christian U Blank; Maarten L Janmaat; David Satijn; Esther C W Breij; Daniel S Peeper; Paul W H I Parren
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

Review 10.  PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma.

Authors:  Colleen S Curran; Elad Sharon
Journal:  Semin Oncol       Date:  2018-01-06       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.